Prevention | Page 13 | Alzheimer's Prevention Registry

You are here


After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug

Scientists are setting a new course in their quest to treat Alzheimer's disease. The shift comes out of necessity. A series of expensive failures with experimental drugs aimed at a toxic protein called amyloid-beta have led to a change in approach. The most recent disappointment came in March, when drugmaker Biogen and its partner Eisai announced they were halting two large clinical trials of an amyloid drug called aducanumab.

Keeping your blood pressure low could reduce your risk of memory issues

Scientific evidence suggests keeping your top blood pressure number at 130 or below can reduce your risk for memory and thinking problems. Learn more about this study and how you can maintain healthy blood pressure.

Anti-Inflammatories Do Not Protect Against Alzheimer’s Disease

A new study found that the common NSAID naproxen was ineffective at preventing Alzheimer’s disease.

Brain Scans Prevent Alzheimer’s Misdiagnosis and Lead to Better Treatment—But They’re Not Covered By Medicare

An under-utilized tool could help correctly diagnose and manage dementia, leading to better care, according to a new study.

The study, published in the Journal of the American Medical Association (JAMA), found that giving patients a PET scan to get more information about the state of their brains resulted in an altered diagnosis for one in three study participants with dementia or memory problems and changed managment—medications, therapy, counseling, etc.—in two-thirds of patients.

Every senior needs cognitive screening, Alzheimer's Association says

At first, she just forgot a name or two. Then, a few meetings on her schedule. A few months later, LuPita Gutierrez-Parker found herself struggling at work to use computer software she knew intimately.

Biogen Ends Late-Stage Alzheimer’s Trials, Crushing Hopes and Calling Amyloid Into Question

Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two Stage 3 clinical trials that had previously reported positive results. Biogen said the drug, aducanumab, was unlikely to help patients.

Dementia Deaths Have More Than Doubled, According to Report. Here’s What Can Be Done

Dementia is steadily rising in the ranks of causes of death in America, according to a new report released by the National Center for Health Statistics. The most sobering statistic: The rate of Americans who died from dementia has increased from 30.5 deaths per 100,000 people in 2000 to 66.7 in 2017, more than doubling in less than twenty years.

An Alzheimer’s Drug Trial Gave Me Hope, and Then It Ended

I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.

Supplements won't stave off Alzheimer's, doctors warn

As Alzheimer’s disease and dementia affect a growing number of Americans, efforts to keep brain decline at bay have become big business.

But in a piece published in the Journal of the American Medical Association, neurologists at the University of California, San Francisco’s Memory and Aging Center, caution consumers that brain health supplements have no proven benefit, calling them “pseudomedicine.”